Clinical Research Roadmap
Our clinical development programs span neurodevelopment, neurodegeneration, and neuro-oncology—validating Galectin-3 as a master regulator across the human lifespan.
Autism Spectrum Disorder
Investigating the role of Gal-3 blockade in restoring homeostatic brain connectivity by addressing the microglial hyper-activation associated with ASD etiology. Our ASD program is bolstered by a strategic partnership with a leading ASD Foundation.
The Immune Shield Theory
Partnering with UCSF to explore how glioblastoma uses Galectin-3 to evade the immune system, converting immunologically 'cold' tumors into 'hot' ones.
Glioblastoma (GBM) Research Collaboration
Breaking the T-Cell Barrier
Gal-3 creates a barrier preventing T-cells from entering tumors. TB006 is designed to dismantle this barrier and enhance immune infiltration.
Glioblastoma (GBM) is the most common malignant brain tumor in adults and remains highly challenging to treat. Standard therapies, including radiation and chemotherapy (temozolomide, TMZ), often face resistance, leading to poor outcomes.
IIT Clinical Trial
Conducting an Investigator-Initiated clinical trial in recurrent GBM patients to assess TB006 tumor penetration, Gal-3 modulation, safety, tolerability, and early efficacy.
Parkinson’s Disease
While the exact cause of Parkinson's disease remains unknown, it is believed to involve a combination of genetic and environmental factors. Current treatments primarily focus on managing symptoms and improving quality of life, using medications, physical therapy, and in some cases, surgical interventions.
TrueBinding is committed to advancing the science of neurodegeneration. We have recently reached a significant milestone in our clinical pipeline:
Phase 2a Clinical Trial
Scope: Double-blinded, placebo-controlled, multi-center study.
Region: United States.
Status:Recruitment Completed (March 2026).
